Cerebrovascular accident
Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab
Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline
Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes
Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials